Medication adherence
Conditions
Interventions
In the pharmacy, the pharmacist will intervene at the moment of the second dispense when an intervention is appropriate. In the intervention pharmacies for patients with a risk for non-adherence, the
Sponsors
IQ healthcare (Radboudumc), Philips Research, DOH care group
Eligibility
Inclusion criteria
Inclusion criteria: All patients listed in participating pharmacies are included that start with cardiovascular or oral blood glucose lowering medication (no prior dispensing of the same substance during the prior 12 months) during study period. Medication is on a prescription of a GP who is a member of primary care cooperation De Ondernemende Huisarts (DOH) or The Innovative General Practitioner. Furthermore, patients need to give informed consent and also their pharmacist needs to give informed consent that the pharmacy dispense data of his/her patients will be used for this research
Exclusion criteria
Exclusion criteria: Participants that are not considered eligible for participation by the pharmacist due to an inability to provide informed consent will not be invited for participation in the study. Also, when the pharmacist considers participation a too high burden for the specific patient under consideration or doubts the appropriateness of the patient for any other reason, the patient is not invited for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in percentage of patients with an initial high risk of non adherence) with a percentage of days covered (PDC) by medication dispensed in community pharmacies of at least 80% between the intervention and control group, at follow-up at 8 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) the difference in percentage of patients with a score of at least 13 on the Probabilistic Medication Adherence Scale (ProMAS) at follow-up between the intervention and control group; 2) the difference in the ProMAS score at follow-up between intervention and control group as a continuous measure; 3) the positive predictive values of the ProMAS score and the ACE profile measured at baseline in relation to medication adherence at 8 months follow-up; 4) PDC in subgroup of patients with a follow-up period of at least one year after the initial drug dispense. | — |
Contacts
Public ContactMirrian Hilbink-Smolders
Radboud university medical center -Scientific Institute for Quality of Healthcare
Outcome results
None listed